US stock futures muted with Jackson Hole, retail earnings on tap
Investing.com - CytomX Therapeutics Inc reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
CytomX Therapeutics Inc announced earnings per share of $-0.350 on revenue of $16.92M. Analysts polled by Investing.com EPS of $-0.330 on revenue of $18.27M.
CytomX Therapeutics Inc 's are down 35% and is trading at $1.230 , still down 83.67% from its 52 week high of $7.53 set on Wednesday, November 17, 2021.
CytomX Therapeutics Inc follows other major Healthcare sector earnings this month
CytomX Therapeutics Inc's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar